• Initiator Pharma posted a Q2 2026 operating loss of DKK 9.5 million, widening from DKK 3.8 million a year earlier.
• Net loss widened to DKK 9.48 million; loss per share deepened to DKK 0.14 from DKK 0.07.
• Operating cash outflow improved to DKK 4.88 million from DKK 8.27 million; cash fell to DKK 17.07 million at June 30.
• Operating costs rose on higher Phase IIa vulvodynia trial activity, with external R&D costs at DKK 6.24 million versus DKK 376,000.
• Strategy sharpened to prioritize pudafensine, discontinuing IP2018; management still expects vulvodynia Phase IIa topline results by end-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Initiator Pharma A/S published the original content used to generate this news brief on August 21, 2026, and is solely responsible for the information contained therein.